MEDI 6469

Drug Profile

MEDI 6469

Alternative Names: Anti-OX40 monoclonal antibody; MEDI-6469

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator AgonOx; Providence Cancer Center
  • Developer MedImmune; Providence Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; OX40 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer; Diffuse large B cell lymphoma; Prostate cancer; Solid tumours
  • Phase I Colorectal cancer; Head and neck cancer

Most Recent Events

  • 01 Apr 2016 MedImmune completes a phase I/II trial in Solid tumours and Diffuse large B cell lymphoma (Combination therapy, Late-stage disease) in USA (IV) (NCT02205333)
  • 16 Sep 2015 Phase-I/II development in solid tumours is ongoing in USA
  • 01 Sep 2015 Phase-I clinical trials in Colorectal cancer (Metastatic disease) in USA (IV) (NCT02559024)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top